Drug, across the briefings

Zanidatamab across 12 cancers

Zanidatamab appears in 12 of the briefings; its FDA label names 3 of those diseases.

Disease	FDA label	Open Targets stage, on which gene	Trials	Active
Cholangiocarcinoma	label names disease	approved on ERBB2	4	2
Esophageal cancer	label names disease	approved on ERBB2	4	3
Gallbladder cancer	label names disease	approved on ERBB2	2	1
Bladder cancer		approved on ERBB2	2	2
Breast cancer		approved on ERBB2	12	9
Cervical cancer		approved on ERBB2	1	1
Colorectal cancer		approved on ERBB2	9	8
Endometrial cancer		approved on ERBB2	2	2
Gastric cancer		approved on ERBB2	11	7
Lung cancer		approved on ERBB2	4	3
Osteosarcoma		approved on ERBB2	—	—
Small intestine cancer		approved on ERBB2	—	—

The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.